Day OneTuesday, 29 April 2025 - GMT (Greenwich Mean Time, GMTZ)

As European biotech companies continue to evolve, securing investment remains a critical driver for scaling innovations and bringing new therapies to market. With the global biotech sector facing shifting economic and regulatory landscapes, understanding the current and future trends in investment is more vital than ever. This panel brings together leading biotech investors who will share insights into the 2024 investment climate, funding strategies, and the factors shaping investor decisionmaking in Europe. Attendees will gain practical knowledge on how to position their biotech companies to attract capital in a competitive marketplace.

• 2025 funding trends and key biotech sectors attracting investor attention and capital in Europe
• Overcoming Challenges: Addressing investor sentiment related to regulatory shifts, market volatility, and economic conditions
• The growing role of cross-border and cross-industry collaborations in securing investment and scaling European biotech firms

For early-stage biotech companies, securing funding before clinical trials is one of the most complex and critical phases of their journey. The challenge lies in demonstrating value to investors at the pre-clinical stage, where risk is high but potential rewards are significant. This panel brings together early-stage investors who will discuss how they assess pre-clinical biotech companies, key factors driving valuations, and the latest trends shaping early-stage funding. Attendees will leave with insights on how to position their companies for investment and optimize value creation at the earliest stages of development.

• Valuation divers and how investors assess pre-clinical biotech companies and the key metrics that influence early-stage valuations
• Risk vs. Reward: Understanding investor expectations and strategies for mitigating risks in early-stage biotech investments
• New trends in early-stage financing, including venture creation, syndicates, and milestone-based investments

In the rapidly evolving world of biotech, finding the right balance between risks and rewards is crucial for success. As investors seek out “the next big breakthrough,” understanding how to effectively present innovative technologies becomes essential for biotech founders. This session will explore how investors assess potential risks associated with new fields and technologies, and what biotech entrepreneurs can do to position their groundbreaking ideas in the most favorable light. By focusing on key strategies for mitigating risks and maximizing rewards, participants will gain valuable insights into the dynamic landscape of biotech investment.

• Assessing Risk: How investors evaluate risk, especially when venturing into uncharted technologies and fields
• Exploring investment trend and the current appetite for investing in groundbreaking biotech innovations compared to traditional platform technologies
• Keeping Up with Innovation: What captivates investors? Learn how investors stay informed about emerging ideas and what elements pique their interest or raise red flags
• Identifying “Must-Have” Science early on and strategies for spotting essential scientific breakthroughs at their inception

After a successful Series-A and -B, biotech companies face a new set of challenges as they scale operations, expand pipelines, and move closer to commercialization. Securing the right investment at this stage can be pivotal in accelerating growth and navigating the path toward profitability. This panel of seasoned investors will explore strategies for growth-stage funding, including what investors look for in post-Series B biotech ventures and how companies can position themselves to secure the capital needed for large-scale development. Growth-stage biotechs will gain valuable insights into optimizing funding to fuel their next phase of expansion.

• What growth-stage investors seek in growth-stage biotechs, including financial performance, strategic vision, and risk management
• Best practices for deploying Series A+ funding effectively to support R&D, clinical trials, and market expansion
• How to balance ongoing investment with long-term goals such as acquisition, partnerships, or IPO preparation

The biotech sector has experienced significant market fluctuations, with public companies facing both opportunities and challenges in navigating today’s market environment. For biotech companies nearing or already in the public stage, understanding the nuances of market sentiment, investor expectations, and timing strategies is critical for sustained success. In this panel, seasoned investors and market experts will explore the current state of public markets for biotech, offering insights on navigating volatility, optimizing investor relations, and making strategic decisions in an evolving financial landscape. Growth and public-stage biotechs will learn how to effectively position themselves in this complex environment.

• Current market conditions and understanding the key drivers of market dynamics and trends impacting public biotech companies in 2025
• How public and institutional investors are evaluating biotech companies and adjusting their strategies
• Best practices for navigating capital raises, stock performance, and communications with shareholders in a fluctuating market